Transthera-B surges 20% on two clinical trial milestones for cancer drugs

Transthera-B secured NMPA approval for a Phase II trial of its TT-01488 regimen in mantle cell lymphoma and completed enrollment in a registrational Phase III study for cholangiocarcinoma, sending shares up 19.91%.

The National Medical Products Administration approved the Phase II trial on July 1, while the global multi-center Phase III study of its core candidate Tinengotinib (TT00420) for advanced cholangiocarcinoma reached its planned patient enrollment target, the company said in a filing.

The stock opened 9.61% higher and extended gains to trade at HKD 13.85, with 7.614 million shares changing hands for HKD 102 million in turnover. Short selling data as of June 30 showed short interest at 0.128% of outstanding shares.

The dual milestones advance two distinct pipeline programs. TT-01488 tablets combined with an anti-CD20 monoclonal antibody regimen targets mantle cell lymphoma, a rare B-cell non-Hodgkin lymphoma accounting for about 6% of all non-Hodgkin lymphoma cases in the US. Standard treatments include Bruton's tyrosine kinase inhibitors such as AbbVie's Imbruvica and AstraZeneca's Calquence, but patients frequently relapse. Anti-CD20 antibodies like Roche's rituximab are a cornerstone of B-cell lymphoma therapy, and combining them with TT-01488 aims to improve outcomes in relapsed or refractory patients by targeting multiple disease pathways.

Tinengotinib, the company's lead asset, is being evaluated for patients with advanced cholangiocarcinoma, a bile duct cancer with a five-year survival rate below 20% for metastatic disease. The drug targets FGFR and other kinase pathways implicated in the disease. Completing enrollment in a global multi-center trial of this scale moves the program closer to potential regulatory submission. Competitors in the FGFR inhibitor space include Incyte's Pemazyre and Taiho Oncology's Lytgobi, though Tinengotinib's differentiated kinase profile may offer advantages in patients with specific FGFR gene alterations.

Transthera-B has built a pipeline centered on kinase inhibitors for oncology, with multiple programs spanning preclinical through Phase III development. The company's cash position and burn rate will determine how far these programs can advance without additional financing or partnership deals — a key consideration for biotech investors. Transthera-B shares, trading at HKD 13.85 after the surge, now reflect market optimism around both programs. Successful Phase II data for TT-01488 and positive Phase III results for Tinengotinib could significantly expand the company's addressable market, though both programs remain years from potential commercialization and face the inherent risks of clinical-stage drug development.

This article is for informational purposes only and does not constitute investment advice.